



Biomarkers and aspects in acute stroke
Biomarcadores e ASPECTS no AVC agudo
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In the last decades there was a surge of research on serum haematological, biochemical and immunological biomarkers in stroke, which unfortunately has not yet translated into clinical practice. Serum biomarkers can theoretically be useful for the diagnosis, progno-sis, and understanding of the pathophysiology and eventually for the selection of treat-
ments in stroke care. Ideally a biomarker or a set of biomarkers can identify a stroke, in the pre-
hospital setting, prior to neuroimaging, similarly to what is done for myocardial infarction1,2. 
Several other molecules can be useful biomarkers of recanalization and reperfusion, of open-
ing of collaterals, of the several steps of the ischemic cascade and of the early neuroinflamma-
tory and neuroregenerative response3,4. Inflammatory molecules might become both biomark-
ers and therapeutic targets for stroke management5.
In this issue of Arquivos de Neuro-Psiquiatria, Aline M. Mourão and co-workers conducted 
an exploratory cross-sectional study of the clinical and molecular correlates of the ASPECTS 
scale score in the 50 patients within the first 24h of acute stroke6. They measured several bio-
markers mainly related to inflammation (BDNF, VCAM-1, VEGF, IL-1β, sTNFRs and adiponec-
tin) and correlated their values with the score in the ASPECTS, a well-known and validated 
scale to grade the extent of an acute ischemic infarct as depicted on non-contrast brain CT. 
They found an association of adiponectin levels and ASPECTS scores. On regression analysis, 
adiponectin and NIHSS were independent predictors of ASPECTS scores.
Adiponectin is an anti-inflammatory adipokine, which also has anti-atherosclerotic prop-
erties. Elevated adiponectin levels indicating an intense inflammatory response are an inde-
pendent predictor of cardiovascular and all-cause mortality in patients with coronary heart 
disease7. Adiponectin levels do not appear to be related to stroke risk8,9.  
This exploratory study has a very promising and innovative result, by establishing an asso-
ciation between adiponectin levels and acute infarct size. Previous studies have described 
associations between high levels of adiponectin and stroke mortality, neurological severity as 
measured by the NIHSS and functional outcome10,11,12.
As the authors themselves recognise in the final part of the discussion, their study has sev-
eral limitations, including cross-sectional design, no evaluation of mortality and functional 
status at 3 or 6 months, small sample size with young median age, selection bias, multiple 
statistical comparisons, and using linear regression for scale scores. As they also point, fur-
ther confirmatory studies are needed. Nevertheless, adiponectin looks like to be a promising 
biomarker for stroke severity and outcome. Mourão et al. findings may be also an additional 
reason for not stopping statins in acute stroke patients13.
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